MCID: TRN018
MIFTS: 54

Transitional Cell Carcinoma malady

Rare diseases, Nephrological diseases, Cancer diseases categories

Aliases & Classifications for Transitional Cell Carcinoma

About this section

Aliases & Descriptions for Transitional Cell Carcinoma:

Name: Transitional Cell Carcinoma 8 42 10
Transitional Cell Carcinoma of Bladder 61
Carcinoma, Transitional Cell 61
Carcinoma Transitional Cell 44
 
Transitional Cell Neoplasm 61
Urothelial Cell Carcinoma 8
Transitional Cell Tumor 8
Transitional Carcinoma 8


Classifications:



External Ids:

Disease Ontology8 DOID:2671
NCIt39 C4030, C2930
MeSH33 D002295

Summaries for Transitional Cell Carcinoma

About this section
Wikipedia:64 Transitional cell carcinoma (TCC, also urothelial cell carcinoma or UCC) is a type of cancer that... more...

MalaCards based summary: Transitional Cell Carcinoma, also known as transitional cell carcinoma of bladder, is related to bladder transitional cell carcinoma and inverted papilloma. An important gene associated with Transitional Cell Carcinoma is ERBB2 (v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2), and among its related pathways are TP53 network and Transcriptional activation of cell cycle inhibitor p21. The compounds topotecan and temozolomide have been mentioned in the context of this disorder. Affiliated tissues include kidney, prostate and ovary, and related mouse phenotypes are pigmentation and hearing/vestibular/ear.

Disease Ontology:8 A carcinoma that derives from transitional epithelial cells.

Related Diseases for Transitional Cell Carcinoma

About this section

Diseases related to Transitional Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 176)
idRelated DiseaseScoreTop Affiliating Genes
1bladder transitional cell carcinoma32.4TP53, IFI27
2inverted papilloma31.3IFI27, KRT13
3papilloma31.1TP53, IFI27, KRT13, CDKN1A
4bladder cancer, somatic30.9TP53, ERBB2, EGFR
5lung cancer30.5TP53, ERBB2, CDKN1A, EGFR
6colorectal cancer30.3FGF3, EGFR, CDKN1A, TP53
7endometrial cancer30.2TP53, IFI27, ERBB2, EGFR, FGF3
8retinoblastoma30.1TP53, IFI27, ERBB2, CDKN1A, EGFR, FGF3
9melanoma29.9TP53, IFI27, NOTCH1, CDKN1A, CGB, FGF3
10prostate cancer29.8PRSS8, IFI27, ERBB2, CDKN1A, EGFR, CGB
11adenoma29.8TP53, IFI27, NR2F1, KRT13, CDKN1A, CGB
12adenocarcinoma29.5IFI27, PRSS8, MMP10, TP53, ERBB2, KRT13
13prostatitis10.8
14invasive bladder transitional cell carcinoma10.6
15sarcomatoid transitional cell carcinoma10.6
16prostate transitional cell carcinoma10.5
17endotheliitis10.5
18renal cell carcinoma10.5
19urethritis10.5
20ovary transitional cell carcinoma10.5
21renal pelvis transitional cell carcinoma10.5
22tongue cancer10.5CDKN1A
23superior vena cava syndrome10.5CGB
24fallopian tube transitional cell carcinoma10.4
25bartholin's gland transitional cell carcinoma10.4
26ureter transitional cell carcinoma10.4
27horseshoe kidney10.4
28transitional cell carcinoma of the corpus uteri10.4
29giant cell glioblastoma10.4EGFR
30esophageal cancer10.4TP53, EGFR
31kidney pelvis sarcomatoid transitional cell carcinoma10.4
32urethra transitional cell carcinoma10.4
33endometrial transitional cell carcinoma10.4
34collecting duct carcinoma10.4
35urachal cyst10.4
36non-papillary transitional cell carcinoma of the bladder10.4
37biliary tract neoplasm10.4ERBB2, EGFR
38li-fraumeni syndrome10.4CDKN1A, TP53
39malignant mixed mullerian tumor10.4TP53, ERBB2
40inflammatory breast carcinoma10.4EGFR, ERBB2
41breast cancer10.4TP53, ERBB2, CDKN1A
42ductal carcinoma in situ10.3TP53, ERBB2, EGFR
43breast ductal carcinoma10.3TP53, ERBB2, EGFR
44stomach cancer10.3ERBB2, TP53
45infiltrating ureter transitional cell carcinoma10.3
46urethral diverticulum10.3
47papillary transitional carcinoma10.3
48ureterocele10.3
49leukemoid reaction10.3
50hydronephrosis10.3

Graphical network of the top 20 diseases related to Transitional Cell Carcinoma:



Diseases related to transitional cell carcinoma

Symptoms for Transitional Cell Carcinoma

About this section

Drugs & Therapeutics for Transitional Cell Carcinoma

About this section

Drug clinical trials:

Search ClinicalTrials for Transitional Cell Carcinoma

Search NIH Clinical Center for Transitional Cell Carcinoma

Genetic Tests for Transitional Cell Carcinoma

About this section

Anatomical Context for Transitional Cell Carcinoma

About this section

MalaCards organs/tissues related to Transitional Cell Carcinoma:

31
Kidney, Prostate, Ovary, Lymph node, Endothelial, Lung, Brain, Testes, Cervix, Bone, Breast, Testis, Monocytes, Bone marrow, Spinal cord, Heart, Colon, Adipocyte, Skin, Uterus, Dentritic cells, Neutrophil

Animal Models for Transitional Cell Carcinoma or affiliated genes

About this section

Publications for Transitional Cell Carcinoma

About this section

Articles related to Transitional Cell Carcinoma:

(show top 50)    (show all 1106)
idTitleAuthorsYear
1
Randomized phase III trial of piroxicam in combination with mitoxantrone or carboplatin for first-line treatment of urogenital tract transitional cell carcinoma in dogs. (25619518)
2015
2
Technical solutions to improve the management of non-muscle-invasive transitional cell carcinoma: summary of a European Association of Urology Section for Uro-Technology (ESUT) and Section for Uro-Oncology (ESOU) expert meeting and current and future perspectives. (25646531)
2015
3
Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder. (25897675)
2015
4
Overexpression of flotillin-1 is involved in proliferation and recurrence of bladder transitional cell carcinoma. (24890092)
2014
5
Recurrent transitional cell carcinoma of the bladder: A mixed nested variant case report and literature review. (22511434)
2012
6
Surgical management for upper urinary tract transitional cell carcinoma (UUT-TCC): a systematic review. (22759317)
2012
7
Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor. (23018212)
2012
8
Prognostic significance of P27 (Kip 1) and MUC1 in papillary transitional cell carcinoma of the urinary bladder. (21346826)
2011
9
Ureterectomy and ureteral reimplatation for low-grade transitional cell carcinoma: is the laparoscopic approach feasible and effective? (21826883)
2011
10
Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. (19443884)
2009
11
Retroperitoneal lymph nodes in transitional cell carcinoma of the kidney and ureter. (19190765)
2009
12
Gemcitabine, paclitaxel, and cisplatin as combined adjuvant approach in transitional cell carcinoma of the urothelium. (19773726)
2009
13
Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas. (19033864)
2009
14
Transitional cell carcinoma in renal transplant recipients: a single center experience. (18184173)
2008
15
Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. (18272914)
2008
16
Upper urinary tract transitional cell carcinoma. A 10-year experience. (18468339)
2008
17
Adenoviral receptor expression of normal bladder and transitional cell carcinoma of the bladder. (17293658)
2007
18
Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group. (17011058)
2006
19
Evaluation of superficial bladder transitional-cell carcinoma by optical coherence tomography. (15989448)
2005
20
Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. (16361539)
2005
21
A case of transitional cell carcinoma of the renal pelvis with adenocarcinoma producing CEA and CA19-9]. (15518131)
2004
22
Cyclooxygenase-2 parallels invasive depth and increased MVD in transitional cell carcinoma. (15450303)
2004
23
Comparison of the nuclear matrix protein 22 with voided urine cytology in the diagnosis of transitional cell carcinoma of the bladder. (14685796)
2004
24
Differential expression of CD44 variant isoforms by cell lines and tissue specimens of transitional cell carcinomas. (14981907)
2003
25
Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome. (12796695)
2003
26
Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma. (12576464)
2003
27
Cathepsins B, H, and L activities in urine of patients with transitional cell carcinoma of the bladder. (11834417)
2002
28
p53 and bcl-2 overexpression as associated risk factors in patients 40 years old or less with transitional cell carcinoma of the bladder. (11464113)
2001
29
Urinary cytokeratin 20 as a marker for transitional cell carcinoma. (10765100)
2000
30
Correlative expression of glutathione S-transferase-pi and multidrug resistance associated protein in bladder transitional cell carcinoma. (12840920)
2000
31
Screening for transitional cell carcinoma of the bladder with trophoblastic differentiation in Upper Galilee]. (10909500)
1998
32
Expression of uroplakin Ib and uroplakin III genes in tissues and peripheral blood of patients with transitional cell carcinoma. (9818021)
1998
33
Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, epidermal growth factor receptor, and bcl-2. (9477105)
1998
34
Correlation of nuclear morphometry and immunostaining for p53 and proliferating cell nuclear antigen in transitional cell carcinoma of the bladder. (9477184)
1997
35
Flow cytometric evaluation of transferrin receptor in transitional cell carcinoma. (9373912)
1997
36
A hot spot for p53 mutation in transitional cell carcinoma of the bladder: clues to the etiology of bladder cancer. (9264274)
1997
37
Results at 43 months' follow-up of a double-blind, randomized, prospective clinical trial using intravesical interferon alpha-2b in the prophylaxis of stage pT1 transitional cell carcinoma of the bladder. (9037279)
1997
38
Detection and clinical pathological significance of the expression of P21, P185, p53 proteins and mutation of ras, p53 genes in transitional cell carcinoma of the bladder]. (9275651)
1996
39
Expression of CD44 splice variants in human transitional cell carcinoma. (8740026)
1996
40
Overexpression of C-erbB3 in transitional cell carcinoma of the ovary]. (8745489)
1995
41
Transitional cell carcinoma of the renal pelvis with choriocarcinomatous differentiation. Immunohistochemical and immunoelectron microscopic assessment of human chorionic gonadotropin production by transitional cell carcinoma of the urinary bladder. (8448745)
1993
42
The rat bladder tumor model system RBT resembles phenotypically and cytogenetically human superficial transitional cell carcinoma. (8171764)
1993
43
Cytokine-induced gene expression of interleukin-8 in human transitional cell carcinomas and renal cell carcinomas. (1739130)
1992
44
Primary localized amyloidosis of the renal pelvis coexisting with transitional cell carcinoma: a case report. (1632328)
1992
45
c-erbB-2 (HER-2/neu) oncopeptide immunoreactivity in localized, high-grade transitional cell carcinoma of the bladder. (1364264)
1992
46
Epidermal nevus with transitional cell carcinomas of the urinary tract. (1802914)
1991
47
Renal transitional cell carcinoma mimicking medullary sponge kidney. (2021801)
1991
48
ABO(H) antigens and beta-2 microglobulin in transitional cell carcinoma. Predictors of response to intravesical bacillus Calmette-Guerin. (1710534)
1991
49
Correlation of the expression of A, B isoantigens with its precursor H antigen in transitional cell carcinoma and the clinical signification of the expression]. (2086062)
1990
50
Nephrogenic adenoma in patients with transitional cell carcinoma of the bladder receiving intravesical thiotepa. (3121867)
1988

Variations for Transitional Cell Carcinoma

About this section

Expression for genes affiliated with Transitional Cell Carcinoma

About this section
Search GEO for disease gene expression data for Transitional Cell Carcinoma.

Pathways for genes affiliated with Transitional Cell Carcinoma

About this section

Pathways related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 44)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
10.0TP53, CDKN1A
2
Show member pathways
10.0CDKN1A, TP53
310.0CDKN1A, TP53
410.0EGFR, ERBB2
5
Show member pathways
AhR pathway36
10.0CDKN1A, EGFR
610.0NOTCH1, EGFR
7
Show member pathways
DNA damage response (only ATM dependent)36
Wnt Signaling Pathway and Pluripotency36
9.8ERBB2, CDKN1A, TP53
89.8TP53, ERBB2, EGFR
9
Show member pathways
9.8EGFR, ERBB2, TP53
10
Show member pathways
Development EGFR signaling via PIP359
Development PDGF signaling via MAPK cascades59
Apoptosis and survival Anti apoptotic action of membrane bound ESR159
Signaling of Hepatocyte Growth Factor Receptor36
Development EGFR signaling via small GTPases59
Development Neurotrophin family signaling59
Apoptosis and survival NGF signaling pathway59
Apoptosis and survival Role of CDK5 in neuronal death and survival59
9.8ERBB2, EGFR, TP53
11
Show member pathways
9.8TP53, ERBB2, EGFR
12
Show member pathways
Translation Non genomic rapid action of Androgen Receptor59
9.8EGFR, CDKN1A, ERBB2
13
Show member pathways
9.8CDKN1A, EGFR, ERBB2
149.8EGFR, CDKN1A, TP53
159.8TP53, CDKN1A, EGFR
169.8TP53, EGFR, CDKN1A
179.8TP53, CDKN1A, EGFR
189.7TP53, RBX1
19
Show member pathways
9.6TP53, ERBB2, CDKN1A, EGFR
209.6EGFR, ERBB2, TP53, CDKN1A
219.6TP53, EGFR, CDKN1A, ERBB2
22
Show member pathways
Signal transduction PTEN pathway59
9.6EGFR, CDKN1A, ERBB2, TP53
23
Show member pathways
ErbB receptor signaling network36
ErbB signaling pathway36
9.6CDKN1A, TP53, ERBB2, EGFR
249.5TP53, CDKN1A, RBX1
25
Show member pathways
Cell cycle36
9.5CDKN1A, RBX1, TP53
26
Show member pathways
9.5ERBB2, FGF3, EGFR, TP53
27
Show member pathways
9.5CDKN1A, EGFR, FGF3, ERBB2
28
Show member pathways
9.5ERBB2, CDKN1A, EGFR, FGF3
29
Show member pathways
9.5ERBB2, CDKN1A, FGF3, EGFR
309.5TP53, EGFR, FGF3, CDKN1A
31
Show member pathways
9.5TP53, NOTCH1, RBX1
329.3CDKN1A, EGFR, NOTCH1, TP53, ERBB2
33
Show member pathways
9.3NOTCH1, ERBB2, TP53, EGFR, CDKN1A
34
Show member pathways
Signaling Pathways in Glioblastoma36
9.3TP53, ERBB2, CDKN1A, EGFR, FGF3
359.3TP53, CDKN1A, FGF3, ERBB2, EGFR
369.3ERBB2, EGFR, CDKN1A, RBX1
37
Show member pathways
Delta-Notch Signaling Pathway36
Notch Signaling Pathway36
9.2TP53, EGFR, RBX1, NOTCH1
38
Show member pathways
9.0TP53, FGF3, ERBB2, RBX1, EGFR
39
Show member pathways
9.0EGFR, FGF3, CDKN1A, RBX1, ERBB2
40
Show member pathways
9.0ERBB2, CDKN1A, RBX1, FGF3, EGFR
418.8RBX1, ERBB2, EGFR, CDKN1A, FGF3, TP53
428.7CDKN1A, FGF3, EGFR, ERBB2, NOTCH1, RBX1
43
Show member pathways
8.6MMP10, ERBB2, NOTCH1, CDKN1A, TP53, FGF3
44
Show member pathways
8.5CDKN1A, FGF3, TP53, EGFR, ERBB2, NOTCH1

Compounds for genes affiliated with Transitional Cell Carcinoma

About this section

Compounds related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 98)
idCompoundScoreTop Affiliating Genes
1topotecan44 1111.5EGFR
2temozolomide44 1111.4CDKN1A, TP53
3hrgbeta14410.2CDKN1A, EGFR, ERBB2
4p000484410.1CDKN1A, IFI27
5optimax4410.1CDKN1A, IFI27
6n-(4-hydroxyphenyl)retinamide4410.1ERBB2, TP53, CDKN1A
7pd1587804410.0EGFR, ERBB2
8jnj 28871063 hydrochloride6010.0EGFR, ERBB2
9taxane4410.0TP53, ERBB2, CDKN1A, EGFR
10suberoylanilide hydroxamic acid4410.0ERBB2, EGFR, TP53, CDKN1A
11oxaliplatin44 50 1112.0EGFR, TP53, ERBB2, CDKN1A
12flavopiridol44 1111.0ERBB2, CDKN1A, TP53, EGFR
13bortezomib44 50 1112.0CDKN1A, ERBB2, TP53, EGFR
14irinotecan44 50 1112.0TP53, ERBB2, CDKN1A, EGFR
15leucovorin44 50 1112.0ERBB2, EGFR, CGB
16geldanamycin44 50 60 1113.0ERBB2, EGFR, TP53, CDKN1A
17gemcitabine44 50 1112.0CDKN1A, TP53, ERBB2, EGFR
18hmba449.9IFI27, CDKN1A, TP53
19ag 1478 hydrochloride609.9EGFR, ERBB2
20docetaxel44 50 60 1112.9ERBB2, EGFR, CDKN1A, TP53
21batimastat44 60 1111.9EGFR, MMP10, ERBB2
22egcg449.9CDKN1A, EGFR, TP53, ERBB2
23curcumin449.9EGFR, ERBB2, TP53, CDKN1A
24indole-3-carbinol449.9IFI27, CDKN1A, TP53
25sulindac44 1110.9TP53, IFI27, CDKN1A
265fluorouracil449.8EGFR, ERBB2, CDKN1A, TP53
27roscovitine449.7CDKN1A, IFI27, TP53
28gefitinib44 50 1111.7IFI27, ERBB2, CDKN1A, EGFR
29ag 490609.7EGFR, ERBB2
30resveratrol44 60 24 1112.7TP53, IFI27, CDKN1A, ERBB2
31adpribose449.7EGFR, CDKN1A, TP53, IFI27
32mg 13244 6010.7CDKN1A, IFI27, EGFR, TP53
33agar449.6ERBB2, CDKN1A, FGF3, EGFR
34thymidylate449.6ERBB2, IFI27, CDKN1A, EGFR, TP53
35n acetylcysteine449.5IFI27, TP53, CDKN1A, EGFR, ERBB2
36tamoxifen44 50 28 1112.5TP53, EGFR, CDKN1A, ERBB2, IFI27
37paclitaxel44 50 1111.5EGFR, ERBB2, CDKN1A, TP53, IFI27
38rapamycin449.5IFI27, ERBB2, EGFR, CDKN1A, NOTCH1
39genistein44 28 60 1 24 1114.4CDKN1A, NOTCH1, ERBB2, IFI27, EGFR
40retinoid449.4CDKN1A, IFI27, EGFR, TP53
41ly294002449.3TP53, IFI27, ERBB2, NOTCH1, CDKN1A, EGFR
42doxorubicin44 50 1111.3ERBB2, TP53, CDKN1A, NOTCH1, EGFR, IFI27
43cisplatin44 50 60 1112.2CGB, TP53, IFI27, ERBB2, CDKN1A, EGFR
44paraffin449.1EGFR, CDKN1A, ERBB2, IFI27, TP53, KRT13
45progesterone44 28 60 24 1113.0CGB, ERBB2, EGFR, NR2F1, IFI27, TP53
46serine448.7EGFR, MMP10, PRSS8, ERBB2, NOTCH1, CDKN1A
47estrogen448.7TP53, IFI27, NR2F1, NOTCH1, CDKN1A, EGFR
48vegf448.4FGF3, TP53, MMP10, IFI27, ERBB2, NOTCH1
49oligonucleotide448.2NR2F1, IFI27, MZF1, FGF3, MMP10, CDKN1A
50retinoic acid44 249.0MZF1, KRT13, NOTCH1, CDKN1A, EGFR, NR2F1

GO Terms for genes affiliated with Transitional Cell Carcinoma

About this section

Cellular components related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1receptor complexGO:00432359.5EGFR, NOTCH1, ERBB2
2nucleoplasmGO:00056548.9CDKN1A, RBX1, NOTCH1, NR2F1, TP53

Biological processes related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 13)
idNameGO IDScoreTop Affiliating Genes
1mitotic cell cycle arrestGO:007185010.2CDKN1A, TP53
2intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorGO:004277110.0CDKN1A, TP53
3positive regulation of epithelial cell proliferationGO:005067910.0EGFR, NOTCH1, ERBB2
4cellular response to ionizing radiationGO:00714799.9CDKN1A, TP53
5cell cycle arrestGO:00070509.8CDKN1A, HEPACAM, TP53
6phosphatidylinositol-mediated signalingGO:00480159.8FGF3, EGFR, CDKN1A, ERBB2
7fibroblast growth factor receptor signaling pathwayGO:00085439.7ERBB2, CDKN1A, EGFR, FGF3
8Fc-epsilon receptor signaling pathwayGO:00380959.7ERBB2, CDKN1A, EGFR, FGF3
9positive regulation of reactive oxygen species metabolic processGO:020003799.7CDKN1A, TP53
10epidermal growth factor receptor signaling pathwayGO:00071739.7ERBB2, CDKN1A, EGFR, FGF3
11neurotrophin TRK receptor signaling pathwayGO:00480119.7ERBB2, CDKN1A, EGFR, FGF3
12Notch signaling pathwayGO:00072199.6TP53, NOTCH1, RBX1
13signal transductionGO:00071659.1NR2F1, ERBB2, EGFR, CGB, FGF3

Molecular functions related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1epidermal growth factor-activated receptor activityGO:000500610.1EGFR, ERBB2
2transmembrane receptor protein tyrosine kinase activityGO:000471410.0EGFR, ERBB2
3receptor signaling protein tyrosine kinase activityGO:00047169.9ERBB2, EGFR
4protein phosphatase bindingGO:00199039.8EGFR, ERBB2, TP53
5protein bindingGO:00055156.7MZF1, TP53, PRSS8, NR2F1, ERBB2, NOTCH1

Sources for Transitional Cell Carcinoma

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet